Publisher’s Spotlight: The Citeline Awards Are Open For Entries!

Deadline For Submissions Is 23 February

Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees. 

Stopwatch (shutterstock_157284068)
• Source: Shutterstock

Drug development is a long and arduous process, more likely to fail than not. That is why we hold the Citeline Awards, to honor the remarkable achievements and the efforts made along the way by biopharma companies as well as companies providing services to the industry. Seize the opportunity to bring recognition and raise awareness of your innovative work in research and development.

The deadline for entries is approaching. Entries received before the 23 February deadline carry a $99 fee, which can be applied toward attendance at the event; the fee for late submissions is $199. Guidance on the submission process is available on the Citeline Awards website. All entries are judged by an independent panel of industry experts.

The 12 award categories recognize a range of activities:

  • Excellence in Rare Disease Drug Development
  • Best Use of Artificial Intelligence in Clinical Trials
  • Excellence in Patient Recruitment and Engagement
  • Best Patient-Facing Technology Initiative
  • Best Sponsor-Facing Technology Initiative
  • Most Successful Early Phase Research (Preclinical & Phase I)
  • Champion of Diversity & Inclusion in Clinical Trials
  • Clinical Partnership of the Year
  • Most Innovative Start-Up Company
  • Clinical Research Team of the Year
  • Excellence in Use of Real-World Data/Evidence
  • Clinical Trial Result of the Year (open to pharma and biotech companies only)

The Citeline Awards will be held 8 May at the Westin Boston Seaport District Hotel. Please join us in celebrating the global community of biopharmaceutical R&D!

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from R&D

  • ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

     
    • By 

    The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

More from Scrip